Belite Bio Submits New Drug Application for Stargardt Disease Treatment

Belite Bio has finalized its New Drug Application submission to the FDA for tinlarebant, an investigational oral treatment for Stargardt disease type 1. This rare inherited retinal condition currently lacks approved therapies, making this submission a potential step forward for patients. The application is supported by positive data from the Phase 3 DRAGON trial.